• Publications
  • Influence
The rising burden of cancer in the developing world.
  • P. Kanavos
  • Medicine
  • Annals of oncology : official journal of the…
  • 1 July 2006
Cancer remains one of the leading causes of morbidity and mortality worldwide. It is predicted that by 2020, the number of new cases of cancer in the world will increase to more than 15 million, withExpand
Assessing the economic challenges posed by orphan drugs
TLDR
Whether the standard methods of HTA are adequate for assisting decisions on patient access to and funding of orphan drugs is discussed and a research agenda is outlined to help understand the societal value of orphan Drugs and issues surrounding their development, funding, and use. Expand
Diabetes expenditure, burden of disease and management in 5 EU countries
TLDR
This report presents a meta-analysis of diabetes prevalence and policies in Europe over the past 25 years that concludes that diabetes prevalence in Europe is increasing, but the number of cases is still low compared to other European countries. Expand
Competition in Off-Patent Drug Markets: Issues, Regulation and Evidence
In recent years health insurers have placed a great deal of emphasis on the ability of generic medicines to deliver significant savings to overstretched health care budgets due to their lower costExpand
Encouraging the use of generic medicines: implications for transition economies.
Generic drugs have a key role to play in the efficient allocation of financial resources for pharmaceutical medicines. Policies implemented in the countries with a high rate of generic drug use, suchExpand
Pharmaceutical Parallel Trade in Europe: Stakeholder and Competition Effects
  • P. Kanavos, Joan Costa-Font
  • Economics
  • 1 October 2005
Pharmaceutical parallel trade in the European Union is a large and growing phenomenon, and hope has been expressed that it has the potential to reduce prices paid by health insurance and consumersExpand
The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis
• Direct savings accruing to statutory health insurance organisations from the conduct of parallel trade are modest both in absolute and relative terms. These savings (in € ‘000) are as follows forExpand
Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium
TLDR
The tender systems for pharmaceuticals in EU Member States: Impact on and implications for stakeholders, and the generics industry, are presented. Expand
Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
TLDR
Availability of medicines in the public sector does not meet the challenge of supplying essential medicines to the entire population, as stated in the Brazilian constitution, and has unavoidable repercussions for affordability, particularly amongst the lower socio-economic strata. Expand
...
1
2
3
4
5
...